Cardiologists persist with anti-inflammatory CVD approach despite Novo drug trial failure

A Novo Nordisk anti-inflammatory drug failed in a cardiovascular trial, but cardiologists maintain that inflammation remains a key driver of CVD and will continue pursuing this therapeutic avenue. The negative result raises uncertainty about the specific mechanism or drug, not the broader hypothesis. This matters for the future of cardiovascular drug development and Novo's pipeline prospects.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works